Anal Intraepithelial Neoplasia clinical trials at University of California Health
2 in progress, 1 open to eligible people
VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions
open to eligible people ages 18 years and up
This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Electroporation helps pores in your body's cells take in the drug to strengthen your immune system's response. Giving VGX-3100 and electroporation together may work better in treating patients with high-grade anal lesions.
at UCSF
Artesunate Suppositories for the Treatment of HIV-negative Patients With Intra-anal HSIL
Sorry, in progress, not accepting new patients
This is a phase II double blind, placebo-controlled, randomized study of Artesunate suppositories for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
at UCSF
Our lead scientists for Anal Intraepithelial Neoplasia research studies include Chia-Ching (Jackie) Wang Joel Palefsky, MD.
Last updated: